Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:ATCCode |
N06DX03
|
| gptkbp:CASNumber |
1286770-55-5
|
| gptkbp:clinicalTrialPhase |
Phase III (terminated)
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:discontinued |
lack of efficacy
|
| gptkbp:failedIndication |
gptkb:Alzheimer's_disease
|
| gptkbp:hasMolecularFormula |
C17H17F2N3O3S
|
| https://www.w3.org/2000/01/rdf-schema#label |
verubecestat
|
| gptkbp:intendedUse |
gptkb:Alzheimer's_disease
|
| gptkbp:IUPACName |
2-[(1R)-1-(4-fluorophenyl)-2-[(1,2,4-oxadiazol-3-yl)methoxy]ethyl]-5-(trifluoromethyl)thiophene-3-carboxamide
|
| gptkbp:mechanismOfAction |
BACE1 inhibitor
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2103886
46224516 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
development discontinued
|
| gptkbp:synonym |
MK-8931
|
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:bfsParent |
gptkb:MK-0826
|
| gptkbp:bfsLayer |
7
|